Acrivon Therapeutics opened higher at $1.60, compared with its previous close of $1.57. In the last trading session, the stock traded between $1.51 and $1.60. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 4 years ago in Acrivon Therapeutics is now worth
$ 8.70
Resulting in a loss of
$ 91.30 (91.30%)
Invest with $1
Note: Past profits do not guarantee future returns.
Acrivon Therapeutics acquired ACR-525, a Phase 2-ready JAK1 inhibitor, from Aqilion AB. The deal establishes immunology and inflammation as a strategic pillar alongside oncology. Transaction includes undisclosed cash payment with no future royalties or milestones. ACR-525 targets eosinophilic esophagitis with potential applications in inflammatory bowel disease.
6 days ago
31Aug
Acrivon Therapeutics appoints Michaela Levin as chief business officer
Acrivon Therapeutics appoints Michaela Levin, Ph.D., as chief business officer effective August 31, 2026. Dr. Levin will lead business development and partnering activities for the company's AP3 platform. She joins from Recursion, formerly Exscientia, where she led acquisitions and strategic negotiations. Inducement awards include 130,000 stock options and 30,000 restricted stock units under Nasdaq Rule 5635(c)(4). Acrivon is advancing lead program ACR-368 in Phase 2 trials for endometrial cancer with FDA Fast Track designation.
2mo ago
13Aug
Acrivon Therapeutics Q2 2026: Net loss narrows to $18.0M, cash at $90.0M
Acrivon Therapeutics reported Q2 2026 results with a net loss of $18.0 million, beating estimates and narrowing YoY losses by 14.5%. R&D spend dropped due to non-recurring milestones, while G&A fell on lower compensation costs. The company holds $90.0 million in cash, funding operations through Q4 2027. Clinically, ACR-368 interim analysis is expected in H2 2026, and ACR-2316 enters dose expansion.
3mo ago
22Jul
Acrivon to present AP3 platform data at AACR D3 Conference
Acrivon Therapeutics will present data on its AP3 platform and ACR-2316 at the AACR D3 Conference, highlighting the platform's role in drug discovery and early clinical responses. ACR-2316 has shown promising results in AP3-predicted tumor types, with a favorable tolerability profile.
